BiomX is a clinical-stage biotech developing bacteriophage therapies — viruses that infect and kill specific bacteria — to treat serious bacterial infections. The core idea is that phage can precisely target pathogenic bacteria, including antibiotic-resistant strains, without disrupting the broader microbiome. BiomX's primary focus is diabetic foot infections (DFI) and diabetic foot osteomyelitis (DFO), conditions that drive roughly 160,000 lower limb amputations annually in the U.S. BiomX has two active programs: BX011, a fixed multi-phage cocktail for broad outpatient use in DFI, and BX211, a personalized therapy that matches a single phage from a proprietary library to the specific bacterial strain in each patient. BX211 produced positive Phase 2 results in early 2025, showing statistically significant reduction in ulcer size. BX011 is now the priority program, following constructive FDA guidance in late 2025 outlining a path to regulatory approval, with a Phase 2a trial planned in coordination with the U.S. Defense Health Agency (DHA). The DHA has provided approximately $40M in non-dilutive funding, given the relevance of phage therapy to combat wound care. BiomX has no approved products or product revenue. The company funds operations through equity issuances and government grants, and its cost structure is dominated by R&D. Following the discontinuation of a third program and insolvency of its Israeli subsidiary in late 2025, BiomX has reduced its workforce to 20 employees and is actively evaluating strategic alternatives while pursuing additional financing to advance BX011.